Trusted Resources: Evidence & Education
Scientific literature and patient education texts
How we manage iron overload in sickle cell patients
source: British Journal of Haematology
year: 2017
authors: Coates TD, Wood JC
summary/abstract:Blood transfusion plays a prominent role in the management of patients with sickle cell disease (SCD), but causes significant iron overload. As transfusions are used to treat the severe complications of SCD, it remains difficult to distinguish whether organ damage is a consequence of iron overload or is due to the complications treated by transfusion. Better management has resulted in increased survival, but prolonged exposure to iron puts SCD patients at greater risk for iron-related complications that should be treated. The success of chelation therapy is dominated by patient adherence to prescribed treatment; thus, adjustment of drug regimens to increase adherence to treatment is critical. This review will discuss the current biology of iron homeostasis in patients with SCD and how this informs our clinical approach to treatment. We will present the clinical approach to treatment of iron overload at our centre using serial assessment of organ iron by magnetic resonance imaging.
organization: Keck School of Medicine, University of Southern CaliforniaDOI: 10.1111/bjh.14575
read more full text
+myBinderRelated Content
-
Health-related quality of life at 1 Year in the drepagreffe trial comparing chronic transfusion to transplantation i...Health is not just defined as the absenc...
-
Prevalence of vitamin D deficiency in sickle cell disease: a systematic reviewVitamin D deficiency has emerged as a pu...
-
Steven Hardy, PhDSteven Hardy, Ph.D. is the Director of P...
-
Gene therapy targets sickle-cell diseaseElliott Vichinsky estimates that at leas...
-
Annual Sickle Cell Disease and Thalassaemia Conference (ASCAT) 2022The Annual Scientific Conference on Sick...
-
Sickle Cell Disease Association of America, Inc., the Sickle Cell Foundation of Georgia, Inc., and the American Red ...The Sickle Cell Disease Associ...
-
Statement on NHLBI Decision to Pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Si...bluebird bio, Inc. suspended its clinica...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.